> ## Documentation Index
> Fetch the complete documentation index at: https://docs.rxvipnetwork.com/llms.txt
> Use this file to discover all available pages before exploring further.

# Clinical Evidence

> Peer-reviewed research and pilot results demonstrating SureDose effectiveness

## Proven Impact

The Tappt® platform powering SureDose has been validated through multiple peer-reviewed studies and clinical trials, demonstrating significant improvements in medication adherence and patient outcomes.

<CardGroup cols={3}>
  <Card title="90.7%" icon="bullseye">
    Average medication adherence rate
  </Card>

  <Card title="58.6%" icon="arrow-trend-down">
    Reduction in medication-related side effects
  </Card>

  <Card title="44.5%" icon="chart-line-up">
    Improvement in symptom severity scores (PRO)
  </Card>

  <Card title="83.5%" icon="users">
    Patient engagement over 1 year
  </Card>

  <Card title="92%" icon="star">
    Patient satisfaction score
  </Card>

  <Card title="75.1" icon="gauge-high">
    System Usability Score (exceeds 68 benchmark)
  </Card>
</CardGroup>

## Published Research

### ASSIST Study (Inflammatory Bowel Disease)

**A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With IBD Therapy**

<Accordion title="Study Details" icon="microscope">
  * **Lead Researchers**: Jordan Axelrad, MD, MPH; Tamar Sapir, PhD; Sara Horst, MD; Raymond Cross, MD
  * **Published**: JMIR Research Protocols (2022), American Journal of Gastroenterology (2024)
  * **Award**: Award-winning presentation at American Telemedicine Association Annual Meeting 2025
  * **Study ID**: [Protocol Publication](https://www.researchprotocols.org/2022/12/e40382/)

  **Key Findings**:

  * Demonstrated significant improvement in adherence rates for IBD medications
  * Real-time monitoring enabled early intervention for side effects
  * Patients reported high satisfaction with tap-to-confirm simplicity
</Accordion>

**Citations**:

* Axelrad J, Long M, Horst S, et al. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and Persistence With Inflammatory Bowel Disease Therapy (ASSIST Study): Protocol for a Randomized Controlled Trial. *JMIR Res Protoc* 2022;11(12):e40382.
* Axelrad J, Sapir T, Horst SN, et al. A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With Inflammatory Bowel DiSease Therapy: Updates From the ASSIST Study. *Am J Gastroenterol* 2024;119(10S):S865-S867.

### SMART Reach Trial (Breast Cancer)

**Systematic Monitoring and Adherence Realization for Treatment in Hormone Receptor-Positive Breast Cancer**

<Accordion title="Study Details" icon="microscope">
  * **Lead Researchers**: Sara Arshad, PhD; Tamar Sapir, PhD; Jane Meisel, MD; Ilana Graetz, PhD
  * **Presented**: Pharmacy Quality Alliance Annual Meeting 2025 (Gold Medal Winner)
  * **Published**: Journal of the American Pharmacists Association (2025)
  * **Also Presented**: American Society of Clinical Oncology (ASCO) 2025

  **Key Findings**:

  * Improved adherence to CDK4/6 inhibitors in breast cancer patients
  * Identified role of social determinants of health in medication adherence
  * Remote monitoring enabled personalized intervention strategies
</Accordion>

**Citations**:

* Arshad S, Sapir T, Carter J, et al. Feasibility Trial of the Systematic Monitoring and Adherence Realization for Treatment in Hormone Receptor-Positive Breast Cancer (SMART Reach). *J Am Pharm Assoc* 2025;65(3):102398. \[Gold Medal Winner]
* Sapir T, Beckmann L, Arshad S, et al. The Role of Social Determinants of Health in Medication Adherence for CDK4/6 Inhibitors in Breast Cancer: Insights From a Remote Monitoring Tool. *J Am Pharm Assoc* 2025;65(3):102398.
* Meisel J, Sapir T, Graetz I, et al. Improving adherence to CDK4/6 inhibitors in breast cancer through remote therapeutic monitoring with real-time adherence tracking and actionable alerts. *JCO* 2025;43:e12520.

### HIV Care Engagement Study

**Improving ART Adherence and HIV Care Engagement Through Multi-Faceted Interventions**

<Accordion title="Study Details" icon="microscope">
  * **Lead Researchers**: Lisa Hightow-Weidman, MD, MPH; Tamar Sapir, PhD; Kelly Pillinger, PharmD, BCIDP
  * **Presented**: IDWeek, October 2025
  * **Study Focus**: Antiretroviral therapy (ART) adherence in HIV patients

  **Key Findings**:

  * Multi-faceted approach combining NFC tracking with patient support
  * Improved engagement with HIV care services
  * Real-time monitoring enabled rapid response to adherence gaps
</Accordion>

**Citation**:

* Hightow-Weidman L, Sapir T, Molloy L, et al. Improving ART Adherence and HIV Care Engagement Through Multi-Faceted Interventions. *IDWeek* 2025. Abstract #2112329.

## Ongoing Clinical Trials

### MONITOR Study (Inflammatory Bowel Disease)

<Info>
  **Study of Efficacy and Adherence to Subcutaneous Vs. Intravenous Vedolizumab Using Remote Monitoring**

  * **ClinicalTrials.gov ID**: [NCT06750731](https://clinicaltrials.gov/study/NCT06750731)
  * **Status**: Active
  * **Focus**: Comparing adherence between different administration routes with remote monitoring support
</Info>

### HCV Tappt Adherence Study

<Info>
  **Hepatitis C Treatment Adherence Monitoring**

  * **ClinicalTrials.gov ID**: [NCT06263829](https://clinicaltrials.gov/study/NCT06263829)
  * **Status**: Active
  * **Focus**: Improving adherence to Hepatitis C therapy through real-time tracking
</Info>

### Renal Pelvic Denervation Pilot

<Info>
  **Renal Pelvic Denervation Adherence Trial**

  * **ClinicalTrials.gov ID**: [NCT07005050](https://clinicaltrials.gov/study/NCT07005050)
  * **Status**: Active
  * **Focus**: Post-procedure medication adherence monitoring
</Info>

## Case Management Applications

### Remote Therapeutic Monitoring (RTM)

<Card title="Growth of RTM Opportunities" icon="chart-line">
  Moreo K, Sapir T. Growth of Remote Therapeutic Monitoring Lands New Opportunities for Case Management. *Prof Case Manag* 2024;29(2):63-69.

  This publication explores how Tappt® technology opens new reimbursement opportunities for pharmacists and case managers through Medicare RTM codes.
</Card>

## Patient Testimonials

<Note>
  **From Published Research**:

  > "I finally haven't felt so alone taking this medicine."
  >
  > — Patient with Breast Cancer (SMART Reach Trial)

  > "With Tappt, we can now add another layer of adherence monitoring to make sure our clients get the right meds at the right time."
  >
  > — Pharmacy Owner (ASSIST Study)
</Note>

## Industry Recognition

<CardGroup cols={2}>
  <Card title="Award-Winning Presentations" icon="trophy">
    * **Gold Medal Winner**: PQA Annual Meeting 2025 (SMART Reach)
    * **Award Winner**: ATA Annual Meeting 2025 (ASSIST Study)
  </Card>

  <Card title="Media Coverage" icon="newspaper">
    * [Refresh Miami](https://refreshmiami.com/news/this-smart-label-for-medications-can-improve-healthcare-outcomes-at-scale/): "This smart label for medications can improve healthcare outcomes at scale" (September 2022)
  </Card>
</CardGroup>

## Regulatory Status

<Warning>
  **Technology**: Tappt® is a smart-label enabled medication engagement and adherence support technology designed to help capture dose activity, support patient engagement, and provide actionable visibility for care teams and pharmacy workflows.

  This technology supports:

  * Medicare RTM reimbursement (CPT codes 98975-98977)
  * Integration with value-based care programs
  * Use in clinical research and trials
</Warning>

## Compare to Industry Standards

| Metric                     | Industry Average | SureDose (Tappt) | Improvement |
| -------------------------- | ---------------- | ---------------- | ----------- |
| Medication Adherence       | \~50%            | 90.7%            | +81%        |
| Patient Retention (1 year) | \~40-60%         | 83.5%            | +39-109%    |
| Patient Satisfaction       | \~70-80%         | 92%              | +15-31%     |
| System Usability (SUS)     | 68 (benchmark)   | 75.1             | +10%        |

## Next Steps

<CardGroup cols={2}>
  <Card title="Implementation Guide" icon="rocket" href="https://www.rxvipnetwork.com/contact">
    Learn how to start using SureDose in your practice
  </Card>

  <Card title="RTM Billing Guide" icon="file-invoice-dollar" href="/suredose/overview">
    Understand reimbursement opportunities
  </Card>
</CardGroup>

***

<Info>
  **Want to participate in research?** Contact our clinical team to learn about ongoing studies and partnership opportunities.
</Info>